Introduction
============

Susceptibility to fungal infections in otherwise healthy individuals with Mendelian disorders are increasingly being recognized ([@B30]) than before the widespread use of genome sequencing. Primary immunodeficiencies consist of various genetic defects that affect the innate and adaptive immune systems. In addition, evaluation of previously healthy, fungus infected patients, suspected of having a primary genetic immunodeficiency may give valuable insights on the role of specific proteins in the immune system for protection from these infections ([@B33]; [@B9]). Caspase recruitment domain containing protein 9 (CARD9) is a central regulator of innate immunity that is highly expressed in neutrophils, macrophages, dendritic cells, and during cell apoptosis in low-serum conditions ([@B2]; [@B24]). Mutations in several proteins involved in the CARD9 signaling protein have been demonstrated to cause primary immunodeficiencies in humans. These mutations cause a decreased production of cytokines from innate immune cells, leading to deficiencies of TH17 and accordingly predispose patients to severe disseminated infections ([@B8]). Severe fungal infections in healthy patients have recently been reported from a few countries, i.e., Algeria, Brazil, France, China, Iran, Morocco and Tunisia ([@B16]; [@B10]; [@B23]; [@B33]; [@B17]) and linked to autosomal recessive CARD9 deficiency. The species involved in these infections are *Trichophyton violaceum, Trichophyton rubrum*, *Candida* species, *Exophiala* species, *Phialophora verrucosa*, *Aspergillus* *fumigatus, Prototheca* *zopfii, and Mucor irregularis.* Some of those etiological agents are plant pathogens, which rarely have been associated with human infection. Highly diverse clinical manifestations from cutaneous to disseminated and progressive infections are observed ([@B5]; [@B7]; [@B25]). Our aim was to evaluate the global frequency, geographic distribution and nature of mutations in patients with CARD9 deficiency associated with fungal infections.

Materials and Methods {#s1}
=====================

The review process involved study of existing published literature of all reported cases with fungal infection due to CARD9 deficiency. To search the published literature, Medline database through PubMed, Embase through Scopus, ISI Web of Science, Science Direct and Google Scholar were used to explore the published literature of patients with severe fungal infection and CARD9 deficiency using the key words "caspase recruitment domain deficiency," "CARD9 deficiency," "autosomal recessive CARD9 deficiency," "primary immunodeficiency," "mutations," "fungal infection" or "invasive fungal diseases," "candidiasis," "deep dermatophytosis," "disseminated phaeohyphomycosis," and "chronic mucocutaneous candidiasis" in different combinations. A total of 21 relevant articles were found using these key words. The extracted data were analyzed using R software version 3.4.1. The chi-square test was utilized to evaluate associations between nominal variables and the *p*-value was estimated using the Monte Carlo method. To compare the differential prevalence of *CARD9* mutations and determine differences in causative agents of fungal infections, odds ratios (ORs) were used. The significance of all ORs, using a 95% Bayesian credible interval (CI), was calculated using Bayesian logistic regression.

Results
=======

The Burden of CARD9 Deficiency Is Positively Correlated With Fungal Infection
-----------------------------------------------------------------------------

To analyze the role of CARD9 deficiency in fungal infection, we reviewed the literature and identified 60 cases until 2018. The total number of patients with severe fungal infection related to CARD9 deficiency has been summarized in **Tables [1A](#T1A){ref-type="table"}**,**[B](#T1B){ref-type="table"}** ([@B4], [@B5], [@B6]; [@B25]; [@B16]; [@B10]; [@B13]; [@B33]; [@B11]; [@B17]; [@B18]; [@B19]; [@B21],[@B22]; [@B1]; [@B14]; [@B20]; [@B26]; [@B35]; [@B3]; [@B15]; [@B27]; [@B36]; [@B31],[@B32]). The age at the time of diagnosis ranged from 4 to 91 years (mean 34.3 ± 17.9 years). Since 1989, a total of 14 countries reported cases of fungal infections associated with CARD9 deficiency (**Figure [1](#F1){ref-type="fig"}**). Although most cases originate from Algeria (North Africa) \[*n* = 12 (21.1%)\], the majority of cases were from several countries in the Asian continent (*n* = 29, 48.3%), with Iran reporting the majority (*n* = 10/29, 34.5%). The main fungal infection associated with CARD9 deficiency was candidiasis (40.3%) followed by deep dermatophytosis (37.3%), phaeohyphomycosis (16.4%) and invasive aspergillosis (3.0%). *T. violaceum*, *T. rubrum*, and *Trichophyton mentagrophytes* were observed as etiological agents of dermatophytosis. *Candida* infections were caused by *C. albicans* and non-*albicans Candida* species in 70.8% and 29.2% of the cases, respectively. *P. verrucosa* (36.4%) represented the major species of phaeohyphomycosis and were only reported from China. Neurological infection (40.5%) was the predominant clinical presentation in *Candida* infected patients followed by chronic mucosal and cutaneous candidiasis (29.7%). The outcome was recorded in 45 cases and 11 (24.4%) expired.

###### 

Prevalence of fungal infections, duration of infections and causative pathogens in patients with CARD9 deficiency.

  Fungal infection                       Duration of infection, mean ( ± SD), year   Nr of cases (%)   Causative agent                 Nr of cases (%)
  -------------------------------------- ------------------------------------------- ----------------- ------------------------------- -----------------
  Dermatophytosis                        37.8 ± 18.7                                 25 (37.3)         *Trichophyton rubrum*           7 (13.0)
  Phaeohyphomycosis                      8.5 ± 6.6                                   11 (16.4)         *Trichophyton violaceum*        8 (14.8)
  Invasive aspergillosis                 \-                                          2 (3.0)           *Trichophyton mentagrophytes*   1 (1.9)
  Mucormycosis                           \-                                          1 (1.5)           *Candida* spp                   5 (9.3)
  Protothecosis                          \-                                          1 (1.5)           *Candida albicans*              17 (31.5)
  Candidiasis                            8.5 ± 10.8                                  27 (40.3)         *Candida dubliniensis*          1 (1.9)
     Mucosal and cutaneous candidiasis   11.5 ± 15.5                                 11 (29.7)         *Candida glabrata*              1 (1.9)
     Neurologic infection                5.3 ± 5.6                                   15 (40.5)         *Phialophora verrucosa*         4 (7.4)
     Chronic candidiasis                 6.5 ± 7.7                                   4 (10.8)          *Exophiala dermatitidis*        1 (1.9)
     Osteomyelitis                       3.3 ± 0.5                                   3 (8.1)           *Exophiala spinifera*           2 (3.7)
     Endophthalmitis                     2.3 ± 1.1                                   3 (8.1)           *Aspergillus fumigatus*         2 (3.7)
     Colitis                             \-                                          1 (2.7)           *Corynespora cassiicola*        2 (3.7)
                                                                                                       *Ochroconis musae*              1 (1.9)
                                                                                                       *Mucor irregularis*             1 (1.9)
                                                                                                       *Prototheca zopfii*             1 (1.9)
                                                                                                                                       

Neurologic infection includes meningoencephalitis, meningitis, and brain abscesses.

###### 

Overview of patient demographics and mutations.

  Condition         Nr of cases (%)   Mutation        Nucleotide change   Domain   Nr of cases (%)
  ----------------- ----------------- --------------- ------------------- -------- -----------------
  **Age (year)**                      HMZ Q289X       c.865C\>T           CCD      16 (25.8)
  \<20              16 (26.7)         HMZ Q295X       c.883C\>T           CCD      11 (17.7)
  21--60            39 (65)           HMZ D274fsX60   c.819-820insG       CCD      5 (8.1)
  \>60              5 (8.3)           HMZ R70W        c.208C\>T           CARD     4 (6.5)
  **Male/female**   30(50)/30(50)     HMZ Y91H        c.271T\>C           CARD     4 (6.5)
  **Country**                         HTZ L64fsX59    c.191--192insTGCT   CARD     3 (4.8)
  Algeria           12 (21.1)         HMZ R101C       c.C301T             CARD     2 (3.2)
  Angola            1 (1.7)           HTZ Q158X       c.472C\>T           CCD      1 (1.6)
  Brazil            1 (1.7)           HTZ G72S        c.214G\>A           CARD     1 (1.6)
  China             9 (15.8)          HTZ R373P       c.1118G\>C          CCD      1 (1.6)
  Egypt             1 (1.7)           HMZ R35Q        c.104G\>A           CARD     1 (1.6)
  France            4 (7.0)           HMZ R18W        c.52C\>T            CARD     1 (1.6)
  Iran              10 (17.5)         HMZ E323del     c.GAG967-969del     CCD      1 (1.6)
  Korea             1 (1.7)           HMZ R101L       c.302G\>T           CARD     1 (1.6)
  Morocco           3 (5.3)           HMZ R57H        c.170G\>A           CARD     1 (1.6)
  Pakistan          1 (1.7)           HMZ M1I         c.3G\>C             CARD     1 (1.6)
  Tunisia           4 (7.0)           HTZ A380P       c.1138G\>C          CCD      1 (1.6)
  Turkey            8 (14.0)          HTZ R317R       c.951G\>A           CCD      1 (1.6)
  United Kingdom    1 (1.7)           HTZ S23X        c.68C\>A            CARD     1 (1.6)
  United States     1 (1.7)           HMZ V261fs      c.781delG           CCD      1 (1.6)
                                      HTZ G62fs       c.184G\>A           CARD     1 (1.6)
                                      HTZ G96del36    c.288C\>T           CARD     1 (1.6)
                                      HTZ T231M       c.692C\>T           CCD      1 (1.6)
                                      HTZ F302del     c.905_907delTCT     CCD      1 (1.6)
                                                                                   

HMZ, homozygous; HTZ, heterozygous; CCD, coiled-coiled domain of CARD9 protein; CARD, CARD domain of CARD9 protein.

![The worldwide distributions of fungal infection cases with CARD9 deficiency.](fmicb-09-02434-g001){#F1}

Associations Among Mutations of the *CARD9* Gene and Infection Status With Fungal Pathogens
-------------------------------------------------------------------------------------------

Overall, 24 different genetic alterations in *CARD9* were described in the 60 patients. Three of those were identified most frequently: homozygous (HMZ) p.Q289X (c.865C \> T), HMZ p.Q295X (c.883C \> T) and HMZ p.D274fsX60 (c.819-820insG), which accounted for 25.8%, 17.7%, and 8.1% of the patients, respectively. Multiple variations in *CARD9* were identified in 8.7% of all cases. The correlation between mutations and fungal infection is shown in **Figure [2](#F2){ref-type="fig"}**. The presence of the HMZ p.Q295X (c.883C \> T) and HMZ p.Q289X (c.865C \> T) mutation was associated with an elevated risk of candidiasis (OR: 1.6; 95% CI: 1.18--2.15; *p* = 0.004) and dermatophytosis (OR: 1.85; 95% CI: 1.47--2.37; *p* \< 0.001), respectively. Also a strong association was evident between the presence of HMZ p.D274fsX60 (c.819-820insG) and disseminated phaeohyphomycosis; 2.42 (95% CI 1.84--3.2, *p* \< 0.001). This study demonstrated that the HMZ p.Q289X (c.865C \> T) mutation had a more than two-fold increased risk of dermatophytosis compared with HMZ p.Q295X (c.883C \> T), *p* \< 0.001. Similarly, HMZ p.Q295X (c.883C \> T) alteration increased by two times the risk of developing candidiasis \[OR: 1.95 (95% CI 1.42-2.69, *p* \< 0⋅001)\] versus dermatophytosis (**Table [2](#T2){ref-type="table"}**). *T. violaceum* infected patients carried a marginally higher frequency of HMZ p.Q289X (c.865C \> T) compared to non-*T. violaceum* dermatophytosis cases (43 vs. 56k%).

![Relation between the types of mutations and different clinical forms. Thick, short, and bold line indicates more reported cases with a mutation and clinical form; and less cases shown with thin and lane lines.](fmicb-09-02434-g002){#F2}

###### 

Analysis of 24 reported mutations among 60 patients with fungal infections.

                                                          Dermatophytosis     Phaeohyphomycosis   Invasive aspergillosis   Candidiasis   Mucormycosis        Protothecosis                                                                                 
  --------------------------- ---------- ---------------- ------------------- ------------------- ------------------------ ------------- ------------------- --------------- ------------------- --------- ------------------- ------- ------------------- -------
  Crude analysis              Mutation   HMZ p.Q289X^∗^   1                   \-                  1                        \-            1                   \-              1                   \-        1                   \-      1                   \-
                                         HMZ p.Q295X      0.53 (0.42--0.67)   \<0.001             1.09 (0.84--1.43)        0.506         1.09 (0.96--1.25)   0.19            1.95 (1.41--2.67)   \<0.001   1 (0.91--1.1)       0.998   1 (0.91--1.1)       0.998
                                         Other            0.44 (0.36--0.52)   \<0.001             1.45 (1.18--1.78)        0.001         1.04 (0.93--1.15)   0.494           1.4 (1.09--1.78)    0.012     1.04 (0.96--1.12)   0.337   1.04 (0.96--1.12)   0.337
                              Domain     CCD^∗^           1                   \-                  1                        \-            1                   \-              1                   \-        1                   \-      1                   \-
                                         CARD             0.64 (0.5--0.83)    0.001               1.11 (0.89--1.38)        0.342         1.03 (0.93--1.15)   0.54            1.37 (1.04--1.81)   0.031     0.98 (0.9--1.05)    0.509   0.97 (0.9--1.05)    0.509
                                                                                                                                                                                                                                                           
  Multivariate analysis^∗∗^   Mutation   HMZ p.Q289X^∗^   1                   \-                  1                        \-            1                   \-              1                   \-        1                   \-      1                   \-
                                         HMZ p.Q295X      0.52 (0.4--0.66)    \<0.001             1.15 (0.84--1.57)        0.412         1.11 (0.94--1.3)    0.197           2.09 (1.43--3.07)   \<0.001   1.02 (0.91--1.15)   0.728   0.96 (0.85--1.08)   0.477
                                         Other            0.48 (0.4--0.58)    \<0.001             1.45 (1.15--1.83)        0.003         1.05 (0.93--1.18)   0.429           1.4 (1.06--1.85)    0.022     1.05 (0.96--1.14)   0.294   1 (0.92--1.09)      0.908
                              Domain     CCD^∗^           1                   \-                  1                        \-            1                   \-              1                   \-        1                   \-      1                   \-
                                         CARD             0.72 (0.57--0.91)   0.007               1.09 (0.87--1.36)        0.468         1.03 (0.93--1.15)   0.582           1.33 (1--1.76)      0.053     0.97 (0.9--1.05)    0.486   0.96 (0.89--1.04)   0.305
                                                                                                                                                                                                                                                           

Levels;

∗∗

The results were adjusted for age and sex;

∗

CCD and HMZ p.Q289X were reference levels in their categories; OR, Odds ratio; CI, Bayesian credible interval; HMZ, homozygote; CCD, coiled-coiled domain; CARD, CARD domain; Mutations in CCD, Q289X, Q295X, R373P, Q158X, D274fsX60, E323del, A380P, R317R, V261fs, T231M, F302del; Mutations in CARD, Y91H, R70W, R35Q, R18W, G62fs, G96del36, R101C, G72S, L64fsX59, R101L, R57H, M11, S23X; Other mutations, Q289X, Q295X are not included.

A Relationship Between *CARD9* Gene Mutations and Specific Geographic Distribution
----------------------------------------------------------------------------------

The pattern of distribution was differed by geographical region in reported cases with *CARD9* mutations. The main mutations in African patients were different from those in Asians; HMZ p.Q289X (c.865C \> T) and HMZ p.R101C (c.C301T), accounting for 75% and 10%, respectively, were the common mutations in Africa. The three most common mutations in Asia were HMZ p.Q295X (c.883C \> T), HMZ p.D274fsX60 (c.819-820insG), and HMZ p.R70W (c.208C \> T), which accounted for 34.5%, 17.2%, and 13.8% of the Asian cases, respectively. Notably, HMZ p.Q289X (c.865C \> T) was the most common mutation observed in 75% of the Algerian patients (9 out of 12), while the HMZ p.Q295X (c.883C \> T) mutation was reported in 8 out of 10 Iranian patients (80%). This finding is important as it provides a relationship between mutation and specific geographic occurrence in these patients.

Discussion
==========

CARD9 deficiency is inherited in an autosomal recessive manner. CARD9 plays an important role in the activation of antifungal mechanisms leading to expression of gene products that initiate the inflammatory cascade ([@B24]; [@B12]). The importance of the CARD9 signaling protein in host defense has been demonstrated in a murine CARD9-/- model with targeted disruptions of innate signaling from the antifungal pattern-recognition receptor, dectin-1, that identifies the β-glucan component of the fungal cell ([@B28]). Defective antifungal clearance and latently infected cells could be the result of impaired CARD9 function ([@B34]; [@B12]). We analyzed the characteristics, distribution, frequency, and relationship between the genotype of the *CARD9* gene mutations and fungal infections among the reported cases. Since the first mutation described in 1989 from Algeria ([@B4]), several mutations have been reported from Africa. However, only few reports are from Europe and America. [@B16], reported a novel *CARD9* mutation, HMZ p.Q289X (c.883C \> T), in seven Iranian patients. In this review, the spectrum of *CARD9* mutations in Asian patients is higher than in African patients. So far, more than 24 mutations in the *CARD9* gene have been reported associated with severe fungal infections. Among these mutations, HMZ p.Q289X (c.865C \> T) was the most common, indicating it is a hot spot in Africa. Infections caused by *T. violaceum* and *C. albicans* dominate, but frequency differ by region. We found a remarkably low prevalence of dermatophyte infection in Asian CARD9 deficiency patients. However, we demonstrate that *Candida* species infection is also uncommon in African patients. Our review showed that the two mutations \[HMZ p.Q289X (c.865C \> T) and HMZ p.Q295X (c.883C \> T)\] are present in 44.3% of the patients. Dermatophytosis due to the HMZ p.Q289X (c.865C \> T) mutation encompass 75% of African cases and 34.5% of Asian patients have candidiasis associated with HMZ p.Q295X (c.883C \> T). However, mutations such as HMZ p.R57H (c.170G \> A), heterozygous (HTZ) p.A380P (c.1138G \> C) and HMZ p.R70W (c.208C \> T) are only found in the United States, United Kingdom, and Turkey, respectively, which suggests that mutations may be specific in particular populations or geographic regions. Another possible explanation is the high rate of consanguinity in many closed groups. Although this autosomal recessive disorder which is rare on a world-wide scale, it may not be rare in some countries. The variations in the gene, which are associated with a specific fungal infection, remain unknown. Asia is the most populous continent in the world and may have a greater genetic burden resulting in more patients with severe fungal infections. Although we cannot exclude other causative factors, our data support the notion that some *CARD9* mutations, circulating in specific geographic regions, could be the contributing factor for fungal infections. However, because of the small sample size, future screening should be conducted to confirm these conclusions. Studying the impact of genetic variation on severe fungal infection will improve our understanding of pathogenesis and may ultimately aid future interventions. CARD9 deficiency should be considered in patients with unexplained progressive fungal infection, as it may allow early initiation of appropriate antifungal treatment. Regular medical follow-up and identification of patients with CARD9 deficiencies is recommended including family members.

Conclusion
==========

In recent years, interest in primary immunodeficiency disorders and opportunistic infections has grown. The current study reviewed 60 reported cases with *CARD9* mutations and severe fungal infections, which may provide more information about the relationship between these mutations, the specific geographic presence and the unique predisposition to a particular fungal disease.
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